71% objective response rate, with 59% of patients achieving a very good partial response or better at the recommended 200…
Data from FGFRi-naïve FGFR2-fusion CCA patients represent subset of September 2022 presentation and remain consistent with previously reported resultsCAMBRIDGE, Mass.,…
CLN-619 demonstrated monotherapy activity across a range of tumor types, including in patients whose cancer had progressed on checkpoint inhibitor…
Data demonstrate objective response rates from 56% to 63% across three independent cohorts of advanced melanoma patients – about double…
As of the data cutoff date, nine of the 14 evaluable patients treated with CUE-101+ KEYTRUDA® (pembrolizumab) demonstrated tumor regression,…
vTv discovered small molecule RAGE inhibitor being developed by Cantex under worldwide development and commercialization agreementHIGH POINT, N.C., May 24,…
Company approaching Phase 2 topline data readout for prevention of post-surgical abdominal adhesions Continued momentum with execution of ongoing dose…
NEW YORK, May 23, 2023 (GLOBE NEWSWIRE) -- Y-mAbs Therapeutics, Inc. (the “Company” or “Y-mAbs”) (Nasdaq: YMAB) a commercial-stage biopharmaceutical…
– Results from the completed Collaborative Health Research Projects (CHRP) study with McMaster University presented at the American Thoracic Society…
WALTHAM, Mass., May 23, 2023 (GLOBE NEWSWIRE) -- Checkpoint Therapeutics, Inc. (“Checkpoint”) (Nasdaq: CKPT), a clinical-stage immunotherapy and targeted oncology…